Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer, Extensive Stage Unresectable

In brief

Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.

Key facts

Study ID

NCT00264134

Run by

Kentuckiana Cancer Institute

People needed

40

Starts

2003-06-01

Expected to finish

2005-10-01

Last updated by the study team

2010-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older unresectable lung cancer measurable or evaluable lesions Karnofsky PS greater than or equal to 60%

You may not qualify if…

• untreated CNS metastases

Where it is running

• Kentuckiana Cancer Institute — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.